News & Views | Published:

DIABETES MELLITUS

Sodium transport in diabetes: two sides to the coin

Nature Reviews Nephrology (2018) | Download Citation

New findings implicate sodium transport in α-cell secretory dysfunction, leading to impaired counter-regulatory responses in diabetes. However, these findings also raise important questions about the tissue-specific roles of sodium transport and suggest that inhibitors of sodium transport may have potentially divergent roles in the pancreas, kidney and heart.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Knudsen, J. G. et al. Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production. Cell Metab. https://doi.org/10.1016/j.cmet.2018.10.003 (2018).

  2. 2.

    Suga, T. et al. SGLT1 in pancreatic alpha cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol. Metab. https://doi.org/10.1016/j.molmet.2018.10.009 (2018).

  3. 3.

    Bonner, C. et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21, 512–517 (2015).

  4. 4.

    Pessoa, T. D. et al. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J. Am. Soc. Nephrol. 25, 2028–2039 (2014).

  5. 5.

    Layton, A. T., Vallon, V. & Edwards, A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am. J. Physiol. Renal Physiol. 308, F1343–F1357 (2015).

  6. 6.

    Lytvyn, Y. et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136, 1643–1658 (2017).

  7. 7.

    von Lewinski, D. et al. Functional effects of glucose transporters in human ventricular myocardium. Eur. J. Heart Fail. 12, 106–113 (2010).

  8. 8.

    Ye, Y. et al. Dapagliflozin attenuates Na+/H+ exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc. Drugs Ther. 32, 553–558 (2018).

  9. 9.

    Baartscheer, A. et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60, 568–573 (2018).

  10. 10.

    Packer, M. et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2, 1025–1029 (2017).

Download references

Author information

Affiliations

  1. Division of Endocrinology and Metabolism, Department of Medicine, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada

    • Julie A. Lovshin
  2. Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

    • David Z. Cherney

Authors

  1. Search for Julie A. Lovshin in:

  2. Search for David Z. Cherney in:

Competing interests

J.A.L. has received consulting fees and/or speaking honorarium from Boehringer Ingelheim, Prometic, Intarcia Therapeutics, Inc., Novo Nordisk, Eli Lilly & Co, Merck and AstraZeneca, and has received operating grant support from Merck and Sanofi. D.Z.C. has received consulting fees and/or speaking honorarium from Janssen, Boehringer Ingelheim-Eli, Lilly, AstraZeneca, Merck, Sanofi and Prometic, and has received operating funds from Janssen, Boehringer Ingelheim-Eli, Lilly, AstraZeneca and Merck.

Corresponding author

Correspondence to Julie A. Lovshin.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41581-018-0106-3

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing